• 1
    Silverstein FE. Improving the gastrointestinal safety of NSAIDs: the development of misoprostol – from hypothesis to clinical practice. Dig Dis Sci 1998;43:44758.
  • 2
    Potts M, Prata N, Walsh J, Grossman A. Parachute approach to evidence based medicine. BMJ 2006;333:701703.
  • 3
    Hale RW, Zinberg S. Use of misoprostal in pregnancy. N Engl J Med 2001;344:5960.
  • 4
    Kulier R, Gulmezoglu AM, Hofmeyr GJ, Cheng LN, Campana A. Medical methods for first trimester abortion. Cochrane Database Syst Rev 2004;(2):CD002855.
  • 5
    von Hertzen H, Piaggio G, Wojdyla D, Marions L, My Huong NT, Tang OS, et al. Two mifepristone doses and two intervals of misoprostol administration for termination of early pregnancy: a randomised factorial controlled equivalence trial. BJOG 2009;116:3819.
  • 6
    Prasad S, Kumar A, Divya A. Early termination of pregnancy by single-dose 800 mug misoprostol compared with surgical evacuation. Fertil Steril 2009;91:2831.
  • 7
    Blanchard K, Shochet T, Coyaji K, Thi Nhu Ngoc N, Winikoff B. Misoprostol alone for early abortion: an evaluation of seven potential regimens. Contraception 2005;72:917.
  • 8
    Faundes A, Fiala C, Tang OS, Velasco A. Misoprostol for the termination of pregnancy up to 12 completed weeks of pregnancy. Int J Gynaecol Obstet 2007;99 (Suppl 2):S1727.
  • 9
    Trinder J, Brocklehurst P, Porter R, Read M, Vyas S, Smith L. Management of miscarriage: expectant, medical, or surgical? Results of randomised controlled trial (miscarriage treatment (MIST) trial). BMJ 2006;332:123540.
  • 10
    Ngoc NT, Blum J, Westheimer E, Quan TT, Winikoff B. Medical treatment of missed abortion using misoprostol. Int J Gynaecol Obstet 2004;87:13842.
  • 11
    Neilson JP, Hickey M, Vazquez J. Medical treatment for early fetal death (less than 24 weeks). Cochrane Database Syst Rev 2006;(3):CD002253.
  • 12
    Sharma D, Singhal SR, Rani XX. Sublingual misoprostol in management of missed abortion in India. Trop Doct 2007;37:3940.
  • 13
    Gemzell-Danielsson K, Ho PC, Gomez Ponce de Leon R, Weeks A, Winikoff B. Misoprostol to treat missed abortion in the first trimester. Int J Gynaecol Obstet 2007;99 (Suppl 2):S1825.
  • 14
    Shwekerela B, Kalumuna R, Kipingili R, Mashaka N, Westheimer E, Clark W, et al. Misoprostol for treatment of incomplete abortion at the regional hospital level: results from Tanzania. BJOG 2007;114:13637.
  • 15
    Dao B, Blum J, Thieb B, Raghavan S, Ouedraego M, Lankoande J, et al. Is misoprostol a safe, effective and acceptable alternative to manual vacuum aspiration for postabortion care? Results from a randomised trial in Burkina Faso, West Africa. BJOG 2007;114:136875.
  • 16
    Weeks A, Alia G, Blum J, Winikoff B, Ekwaru P, Durocher J, et al. A randomized trial of misoprostol compared with manual vacuum aspiration for incomplete abortion. Obstet Gynecol 2005;106:5407.
  • 17
    Gemzell-Danielsson KC, Fiala C, Weeks A. Misoprostol: first-line therapy for incomplete miscarriage in the developing world. BJOG 2007;114:13379.
  • 18
    Phupong V, Taneepanichskul S, Kriengsinyot R, Sriyirojana N, Blanchard K, Winikoff B. Comparative study between single dose 600 microg and repeated dose of oral misoprostol for treatment of incomplete abortion. Contraception 2004;70:30711.
  • 19
    Blum J, Winikoff B, Gemzell-Danielsson K, Ho PC, Schiavon R, Weeks A. Treatment of incomplete abortion and miscarriage with misoprostol. Int J Gynaecol Obstet 2007;99 (Suppl 2):S1869.
  • 20
    WHO. Safe Abortion: Technical and Policy Guidance for Health Systems. Geneva: WHO, 2003.
  • 21
    RCOG. The Care of Women Requesting Induced Abortion. London: Royal College of Obstetricians and Gynaecologists, 2004.
  • 22
    Dickinson JE, Evans SF. The optimization of intravaginal misoprostol dosing schedules in second-trimester pregnancy termination. Am J Obstet Gynecol 2002;186:4704.
  • 23
    Ho PC, Blumenthal PD, Gemzell-Danielsson K, Gomez Ponce de Leon R, Mittal S, Tang OS. Misoprostol for the termination of pregnancy with a live fetus at 13 to 26 weeks. Int J Gynaecol Obstet 2007;99 (Suppl 2):S17881.
  • 24
    Srisomboon J, Pongpisuttinun S. Efficacy of intracervicovaginal misoprostol in second-trimester pregnancy termination: a comparison between live and dead fetuses. J Obstet Gynaecol Res 1998;24:15.
  • 25
    Elhassan EM, Abubaker MS, Adam I. Sublingual compared with oral and vaginal misoprostol for termination of pregnancy with second-trimester fetal demise. Int J Gynaecol Obstet 2008;100:823.
  • 26
    Chittacharoen A, Herabutya Y, Punyavachira P. A randomized trial of oral and vaginal misoprostol to manage delivery in cases of fetal death. Obstet Gynecol 2003;101:703.
  • 27
    Gómez Ponce de León R, Wing D, Fiala C. Misoprostol for intrauterine fetal death. International Journal of Gynecology and Obstetrics 2007;99(Suppl 2):S1903.
  • 28
    Hofmeyr GJ, Gulmezoglu AM. Vaginal misoprostol for cervical ripening and induction of labour. Cochrane Database Syst Rev 2003;(1):CD000941.
  • 29
    Calder AA, Loughney AD, Weir CJ, Barber JW. Induction of labour in nulliparous and multiparous women: a UK, multicentre, open-label study of intravaginal misoprostol in comparison with dinoprostone. BJOG 2008;115:127988.
  • 30
    Wing DA, Ortiz-Omphroy G, Paul RH. A comparison of intermittent vaginal administration of misoprostol with continuous dinoprostone for cervical ripening and labor induction. Am J Obstet Gynecol 1997;177:6128.
  • 31
    Alfirevic Z, Weeks A. Oral misoprostol for induction of labour. Cochrane Database Syst Rev 2009;(2):CD001338.
  • 32
    Kundodyiwa TW, Alfirevic Z, Weeks AD. Low-dose oral misoprostol for induction of labor: a systematic review. Obstet Gynecol 2009;113:37483.
  • 33
    Williams MC, Tsibris JC, Davis G, Baiano J, O’Brien WF. Dose variation that is associated with approximated one-quarter tablet doses of misoprostol. Am J Obstet Gynecol 2002;187:6159.
  • 34
    Crass RE, Vance JR. In vivo accuracy of gravity-flow i.v. infusion systems. Am J Hosp Pharm 1985;42:32831.
  • 35
    Weeks A, Alfirevic Z, Faundes A, Hofmeyr GJ, Safar P, Wing D. Misoprostol for induction of labor with a live fetus. Int J Gynaecol Obstet 2007;99 (Suppl 2):S1947.
  • 36
    Plaut MM, Schwartz ML, Lubarsky SL. Uterine rupture associated with the use of misoprostol in the gravid patient with a previous cesarean section. Am J Obstet Gynecol 1999;180:153542.
  • 37
    Wing DA, Lovett K, Paul RH. Disruption of prior uterine incision following misoprostol for labor induction in women with previous cesarean delivery. Obstet Gynecol 1998;91:82830.
  • 38
    Khan KS, Wojdyla D, Say L, Gülmezoglu AM, Van Look PFA. WHO analysis of causes of maternal death: a systematic review. Lancet; 2006;367:106674.
  • 39
    Gulmezoglu AM, Villar J, Ngoc NT, Piaggio G, Carroli G, Adetoro L, et al. WHO multicentre randomised trial of misoprostol in the management of the third stage of labour. Lancet 2001;358:68995.
  • 40
    National Collaborating Centre for Women’s and Children’s Health. Intrapartum care. Care of healthy women and their babies during childbirth. ROCG Press:London, 2007.
  • 41
    Gulmezoglu AM, Forna F, Villar J, Hofmeyr GJ. Prostaglandins for preventing postpartum haemorrhage. Cochrane Database Syst Rev 2007;(2):CD000494.
  • 42
    Walraven G, Blum J, Dampha Y, Sowe M, Morison L, Winikoff B, et al. Misoprostol in the management of the third stage of labour in the home delivery setting in rural Gambia: a randomised controlled trial. BJOG 2005;112:127783.
  • 43
    Hoj L, Cardoso P, Nielsen BB, Hvidman L, Nielsen J, Aaby P. Effect of sublingual misoprostol on severe postpartum haemorrhage in a primary health centre in Guinea-Bissau: randomised double blind clinical trial. BMJ 2005;331:723.
  • 44
    Derman RJ, Kodkany BS, Goudar SS, Geller SE, Naik VA, Bellad MB, et al. Oral misoprostol in preventing postpartum haemorrhage in resource-poor communities: a randomised controlled trial. Lancet 2006;368:124853.
  • 45
    WHO. WHO Recommendations for the Prevention of Postpartum Haemorrhage. WHO: Geneva, 2006.
  • 46
    Alfirevic Z, Blum J, Walraven G, Weeks A, Winikoff B. Prevention of postpartum hemorrhage with misoprostol. Int J Gynaecol Obstet 2007;99 (Suppl 2):S198201.
  • 47
    Hofmeyr GJ, Ferreira S, Nikodem VC, Mangesi L, Singata M, Jafta Z, et al. Misoprostol for treating postpartum haemorrhage: a randomized controlled trial [ISRCTN72263357]. BMC Pregnancy Childbirth 2004;4:16.
  • 48
    Walraven G, Dampha Y, Bittaye B, Sowe M, Hofmeyr J. Misoprostol in the treatment of postpartum haemorrhage in addition to routine management: a placebo randomised controlled trial. BJOG 2004;111:10147.
  • 49
    Zuberi NF, Durocher J, Sikander R, Baber N, Blum J, Walraven G. Misoprostol in addition to routine treatment of postpartum hemorrhage: a hospital-based randomized-controlled trial in Karachi, Pakistan. BMC Pregnancy Childbirth 2008;8:40.
  • 50
    Lokugamage AU, Sullivan KR, Niculescu I, Tigere P, Onyangunga F, El Refaey H, et al. A randomized study comparing rectally administered misoprostol versus Syntometrine combined with an oxytocin infusion for the cessation of primary post partum hemorrhage. Acta Obstet Gynecol Scand 2001;80:8359.
  • 51
    Mousa HA, Alfirevic Z. Treatment for primary postpartum haemorrhage. Cochrane Database Syst Rev 2007;(4):CD003249.
  • 52
    Blum J, Alfirevic Z, Walraven G, Weeks A, Winikoff B. Treatment of postpartum hemorrhage with misoprostol. Int J Gynaecol Obstet 2007;99 (Suppl 2):S2025.
  • 53
    Fiala C, Gemzell-Danielsson K, Tang OS, von Hertzen H. Cervical priming with misoprostol prior to transcervical procedures. Int J Gynaecol Obstet 2007;99 (Suppl 2):S16871.
  • 54
    Ngai SW, Chan YM, Tang OS, Ho PC. The use of misoprostol for pre-operative cervical dilatation prior to vacuum aspiration: a randomized trial. Hum Reprod 1999;14:213942.
  • 55
    Fong YF, Singh K, Prasad RN. A comparative study using two dose regimens (200 microg or 400 microg) of vaginal misoprostol for pre-operative cervical dilatation in first trimester nulliparae. Br J Obstet Gynaecol 1998;105:4137.
  • 56
    Tang OS, Mok KH, Ho PC. A randomized study comparing the use of sublingual to vaginal misoprostol for pre-operative cervical priming prior to surgical termination of pregnancy in the first trimester. Hum Reprod 2004;19:11014.
  • 57
    Lumbiganon P, Hofmeyr J, Gulmezoglu AM, Pinol A, Villar J. Misoprostol dose-related shivering and pyrexia in the third stage of labour. WHO Collaborative Trial of Misoprostol in the Management of the Third Stage of Labour. Br J Obstet Gynaecol 1999;106:3048.
  • 58
    Tang OS, Gemzell-Danielsson K, Ho PC. Misoprostol: pharmacokinetic profiles, effects on the uterus and side-effects. Int J Gynaecol Obstet 2007;99 (Suppl 2):S1607.
  • 59
    Fiala C, Swahn ML, Stephansson O, Gemzell-Danielsson K. The effect of non-steroidal anti-inflammatory drugs on medical abortion with mifepristone and misoprostol at 13–22 weeks gestation. Hum Reprod 2005;20:30727.
  • 60
    Hamoda H, Ashok PW, Flett GM, Templeton A. Analgesia requirements and predictors of analgesia use for women undergoing medical abortion up to 22 weeks of gestation. BJOG 2004;111:9961000.
  • 61
    Philip N, Shannon C, Winikoff B. Misoprostol and Teratogenicity: Reviewing the Evidence. Population Council and Gynuity Health Projects. New York, 2002.
  • 62
    WHO. WHO Model List of Essential Medicines, 16th edn. WHO: Geneva, 2009.
  • 63
    WHO. Managing Complications in Pregnancy and Childbirth: A Guide for Midwives and Doctors. Geneva: WHO, 2003.